Dave Bell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dave Bell has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ernest K. Amankwah
Department of Pediatrics and Oncology School of Medicine Johns Hopkins University Baltimore Maryland USA
23 shared publications - Jennifer Dean
Cancer and Blood Disorders Institute, Johns Hopkins All Children’s Hospital, St. Petersburg, Florida
23 shared publications - Jennifer Mayer
Cancer and Blood Disorders Institute, Johns Hopkins All Children’s Hospital, St. Petersburg, Florida
23 shared publications - Maua Mosha
Johns Hopkins All Children's Hospital, Division of Pediatric Surgery, St Petersburg, FL, USA
23 shared publications - Xin Yang
Clinical and Translational Science Institute of Southeastern Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin
23 shared publications
Latest Publications
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Top 10 common diagnosis in genitourinary diseases (with each diagnosis code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Top 10 common diagnosis in genitourinary diseases (with each diagnosis code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Supplementary Table S1 shows the ICD-9/10-CM codes for used for identifying patients with ALL/LL and comorbidities
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Supplementary Table S1 shows the ICD-9/10-CM codes for used for identifying patients with ALL/LL and comorbidities
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Top 10 common diagnosis in genitourinary diseases (with each diagnosis code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Top 10 common diagnosis in genitourinary diseases (with each diagnosis code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Top 10 common diagnosis in digestive tract disorders (with each diagnosis code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Top 10 common diagnosis in digestive tract disorders (with each diagnosis code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Supplementary Table S1 shows the ICD-9/10-CM codes for used for identifying patients with ALL/LL and comorbidities
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Supplementary Table S1 shows the ICD-9/10-CM codes for used for identifying patients with ALL/LL and comorbidities
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Top 10 common diagnosis in digestive tract disorders (with each diagnosis code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Top 10 common diagnosis in digestive tract disorders (with each diagnosis code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Data from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Limited knowledge exists on the prevalence of comorbidity among pediatric patients diagnosed with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). To determine the prevalence of comorbidities present within 3 months before diagnosis among pediatric patients with ALL/LL and to examine if the prevalence varies by age, biological sex at birth, and race/ethnicity, we analyzed data of patients diagnosed with ALL/LL at ≤21 years of age from January 1, 2005, to June 30, 2020 (n = 5,455), using electronic health records data from the TriNetX Research Network database. Comorbidities examined included pulmonary, cardiac, cerebrovascular, vascular, developmental, immune, metabolic, infectious, genitourinary, digestive, muscle and connective tissue and central and peripheral nervous system conditions. Overall, the prevalence of comorbidity was 34.1% (n = 1,904), with significant differences observed based on sex and race/ethnicity. Females had a higher prevalence at 36.6% compared with males at 33.6% (P = 0.024). Similarly, non-Hispanic White patients had a higher prevalence of 37.5% compared with 33.1% in other racial/ethnic groups (P < 0.001). Analyses of specific comorbidities revealed notable differences in the prevalence of infectious diseases by biological sex at birth (female: 9.7%, male: 7.0%; P < 0.001) and digestive diseases by age at diagnosis (≤10 years: 13.8%, >10 years: 10.4%; P < 0.001). Although the overall prevalence of comorbidity at diagnosis showed minor differences across groups, disparities exist for specific comorbidities with females and younger patients having a higher prevalence of infectious diseases and digestive tract diseases, respectively. Future studies are needed to evaluate if these differences contribute to the disparities in treatment outcomes.Significance:Among pediatric patients with ALL/LL, significant disparities were found for specific comorbidities, particularly among females and younger patients who had higher rates of digestive tract diseases and infectious diseases. These findings are important as comorbidities can be considered in clinical decision-making in the management and treatment of these patients.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Limited knowledge exists on the prevalence of comorbidity among pediatric patients diagnosed with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). To determine the prevalence of comorbidities present within 3 months before diagnosis among pediatric patients with ALL/LL and to examine if the prevalence varies by age, biological sex at birth, and race/ethnicity, we analyzed data of patients diagnosed with ALL/LL at ≤21 years of age from January 1, 2005, to June 30, 2020 (n = 5,455), using electronic health records data from the TriNetX Research Network database. Comorbidities examined included pulmonary, cardiac, cerebrovascular, vascular, developmental, immune, metabolic, infectious, genitourinary, digestive, muscle and connective tissue and central and peripheral nervous system conditions. Overall, the prevalence of comorbidity was 34.1% (n = 1,904), with significant differences observed based on sex and race/ethnicity. Females had a higher prevalence at 36.6% compared with males at 33.6% (P = 0.024). Similarly, non-Hispanic White patients had a higher prevalence of 37.5% compared with 33.1% in other racial/ethnic groups (P < 0.001). Analyses of specific comorbidities revealed notable differences in the prevalence of infectious diseases by biological sex at birth (female: 9.7%, male: 7.0%; P < 0.001) and digestive diseases by age at diagnosis (≤10 years: 13.8%, >10 years: 10.4%; P < 0.001). Although the overall prevalence of comorbidity at diagnosis showed minor differences across groups, disparities exist for specific comorbidities with females and younger patients having a higher prevalence of infectious diseases and digestive tract diseases, respectively. Future studies are needed to evaluate if these differences contribute to the disparities in treatment outcomes.Significance:Among pediatric patients with ALL/LL, significant disparities were found for specific comorbidities, particularly among females and younger patients who had higher rates of digestive tract diseases and infectious diseases. These findings are important as comorbidities can be considered in clinical decision-making in the management and treatment of these patients.
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Supplementary Table S1 shows the ICD-9/10-CM codes for used for identifying patients with ALL/LL and comorbidities
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Supplementary Table S1 shows the ICD-9/10-CM codes for used for identifying patients with ALL/LL and comorbidities
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Top 10 common diagnosis in genitourinary diseases (with each diagnosis code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Top 10 common diagnosis in genitourinary diseases (with each diagnosis code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Top 10 common diagnosis in digestive tract disorders (with each diagnosis code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at Diagnosis
Top 10 common diagnosis in digestive tract disorders (with each diagnosis code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)